Get the top three things to know in women's health + wellness, every weekday:

Preliminary Results Are Good for Non-Surgical Endometriosis Test

What: Hera Biotech company said they got good interim results from clinical trials of their endometriosis diagnostic tool. In the first 38 patients tested, the diagnostic test, which looks at swabbed endometrial cells, has an accuracy rate of 94%.

Why it matters: More data is needed, but Hera CEO said the result “suggests that Hera’s molecular diagnostic test has the potential to replace surgical diagnosis and greatly improve the woefully inadequate state of endometriosis diagnosis and treatment that exists today.”

SourceHera Biotech via BusinessWire

More News Snippets
Alcohol’s Lies (and Breast Cancer)

A deep dive on drinking and examining why people reacted far more swiftly to the news that smoking causes cancer than they have for alcohol—especially breast cancer.

Could Ozempic Prevent Fibroids?

Women with type 2 diabetes who got a GLP-1 medication were less likely to develop new fibroids than women who just took metformin, a diabetes medication.

OBGYN Pain Goes Beyond IUDs

Sharing the stories of women who have had fibroids removed without pain medication or endometriosis symptoms ignored for years.

Saving the Tiniest Babies

Advances in neonatal care now make it possible to save extremely premature babies, some born as early as 22 weeks.